title: Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
abstract: OBJECTIVE
  Guidelines for management of postchemotherapy residual mass in patients with advanced seminoma remain controversial. We sought to characterize independent prognostic factor(s) for persistence of tumor to identify patients with a high risk of residual carcinoma.
  
  
  METHODS
  One hundred four patients with advanced seminoma were assessed. All had achieved a complete response or partial response with normal markers to induction cisplatin-based chemotherapy and had radiographs available for review. Selected prechemotherapy and postchemotherapy characteristics were compared for patients who had either germ cell tumor histology at surgery or relapsed at the assessed site (defined as site failure) versus those who had only necrosis or fibrosis found at surgery and did not relapse at the assessed site (defined as site nonfailure).
  
  
  RESULTS
  At a median follow-up time of 47 months (range, 5 to 153), 94 patients (90%) were designated as site nonfailures and 10 (10%) as site failures. Site failure correlated only with size of the residual mass (< 3 cm or normal v > or = 3 cm; P = .0006). Two of 74 patients (3%) with residual masses less than 3 cm were considered site failures, compared with eight of 30 (27%) with residual masses > or = 3 cm.
  
  
  CONCLUSIONS
  Patients with advanced seminoma who have normal radiographs or residual masses less than 3 cm after chemotherapy can be observed without further intervention. The following three options exist for patients with a residual mass > or = 3 cm: observation, radiotherapy, or surgical intervention. We prefer the latter to define response, resect viable tumor when possible, and direct further treatment.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Puc
authors.forename: R
authors.initials: R
authors.lastname: Heelan
authors.forename: M
authors.initials: M
authors.lastname: Mazumdar
authors.forename: H
authors.initials: H
authors.lastname: Herr
authors.forename: J
authors.initials: J
authors.lastname: Scheinfeld
authors.forename: V
authors.initials: V
authors.lastname: Vlamis
authors.forename: D F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: G J
authors.initials: GJ
authors.lastname: Bosl
authors.forename: P
authors.initials: P
authors.lastname: Mencel
authors.forename: R J
authors.initials: RJ
authors.lastname: Motzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D018239:Seminoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin